BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35045126)

  • 1. Identification of hub genes associated with COVID-19 and idiopathic pulmonary fibrosis by integrated bioinformatics analysis.
    Chen Q; Xia S; Sui H; Shi X; Huang B; Wang T
    PLoS One; 2022; 17(1):e0262737. PubMed ID: 35045126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients.
    Mahmud SMH; Al-Mustanjid M; Akter F; Rahman MS; Ahmed K; Rahman MH; Chen W; Moni MA
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33847347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Validation of Potential Biomarkers and Pathways for Idiopathic Pulmonary Fibrosis by Comprehensive Bioinformatics Analysis.
    Qian W; Cai X; Qian Q; Zhang X
    Biomed Res Int; 2021; 2021():5545312. PubMed ID: 34285914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network-based identification genetic effect of SARS-CoV-2 infections to Idiopathic pulmonary fibrosis (IPF) patients.
    Taz TA; Ahmed K; Paul BK; Kawsar M; Aktar N; Mahmud SMH; Moni MA
    Brief Bioinform; 2021 Mar; 22(2):1254-1266. PubMed ID: 33024988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Hub Genes in Idiopathic Pulmonary Fibrosis and Their Association with Lung Cancer by Bioinformatics Analysis.
    Velázquez-Enríquez JM; Reyes-Avendaño I; Santos-Álvarez JC; Reyes-Jiménez E; Vásquez-Garzón VR; Baltiérrez-Hoyos R
    Adv Respir Med; 2023 Oct; 91(5):407-431. PubMed ID: 37887075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing.
    Islam MA; Kibria MK; Hossen MB; Reza MS; Tasmia SA; Tuly KF; Mosharof MP; Kabir SR; Kabir MH; Mollah MNH
    Sci Rep; 2023 Mar; 13(1):4685. PubMed ID: 36949176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated bioinformatics analysis for the identification of idiopathic pulmonary fibrosis-related genes and potential therapeutic drugs.
    Zhang Z; Guan Q; Tian Y; Shao X; Zhao P; Huang L; Li J
    BMC Pulm Med; 2023 Oct; 23(1):373. PubMed ID: 37794454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioinformatics analysis on differentially expressed genes of alveolar macrophage in IPF.
    Wang H; Wang M; Xiao K; Zhang X; Wang P; Xiao S; Qi H; Meng L; Zhang X; Shen F
    Exp Lung Res; 2019; 45(9-10):288-296. PubMed ID: 31762326
    [No Abstract]   [Full Text] [Related]  

  • 9. An integrative bioinformatics analysis for identifying hub genes associated with infection of lung samples in patients infected with SARS-CoV-2.
    Xie TA; He ZJ; Liang C; Dong HN; Zhou J; Fan SJ; Guo XG
    Eur J Med Res; 2021 Dec; 26(1):146. PubMed ID: 34920753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
    Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
    J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of diagnostic hub genes related to neutrophils and infiltrating immune cell alterations in idiopathic pulmonary fibrosis.
    Lin Y; Lai X; Huang S; Pu L; Zeng Q; Wang Z; Huang W
    Front Immunol; 2023; 14():1078055. PubMed ID: 37334348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction and analysis of genetic effect in idiopathic pulmonary fibrosis and gastroesophageal reflux disease.
    Chen P; Xie L; Ma L; Zhao X; Chen Y; Ge Z
    IET Syst Biol; 2023 Dec; 17(6):352-365. PubMed ID: 37907428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis.
    Giriyappagoudar M; Vastrad B; Horakeri R; Vastrad C
    Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis and Identification Genetic Effect of SARS-CoV-2 Infections to Alzheimer's Disease Patients by Integrated Bioinformatics.
    Wang F; Xu J; Xu SJ; Guo JJ; Wang F; Wang QW
    J Alzheimers Dis; 2022; 85(2):729-744. PubMed ID: 34776447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of potential therapeutic drugs against SARS-CoV-2 by using Connectivity Map based on transcriptome data.
    Chen WY; Fang ZX; Lv XD; Zhou QH; Yao M; Deng M
    Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):3122-3131. PubMed ID: 33877681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration and validation of related hub gene expression during SARS-CoV-2 infection of human bronchial organoids.
    Fang KY; Cao WC; Xie TA; Lv J; Chen JX; Cao XJ; Li ZW; Deng ST; Guo XG
    Hum Genomics; 2021 Mar; 15(1):18. PubMed ID: 33726831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of hub genes in rheumatoid arthritis through an integrated bioinformatics approach.
    Wu R; Long L; Zhou Q; Su J; Su W; Zhu J
    J Orthop Surg Res; 2021 Jul; 16(1):458. PubMed ID: 34271942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The networks of m
    Li X; Peng C; Zhu Z; Cai H; Zhuang Q
    Aging (Albany NY); 2021 Mar; 13(5):6273-6288. PubMed ID: 33647885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using bioinformatics approach identifies key genes and pathways in idiopathic pulmonary fibrosis.
    Xu Z; Mo L; Feng X; Huang M; Li L
    Medicine (Baltimore); 2020 Sep; 99(36):e22099. PubMed ID: 32899090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis.
    Kou W; Li B; Shi Y; Zhao Y; Yu Q; Zhuang J; Xu Y; Peng W
    BMC Cancer; 2022 Jan; 22(1):110. PubMed ID: 35078421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.